By: IPP Bureau
Last updated : September 07, 2026 8:47 am
The buyback will be primarily funded through proceeds from Fosun Pharma’s disposal of approximately 6% of its equity stake in Gland Pharma, for total consideration of around US$294 million
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma) has announced an H-share repurchase plan of up to HK$1 billion, with the repurchased shares to be either cancelled or held as treasury shares.
The company said the programme has come into effect and will be implemented as soon as practicable, with management describing the move as a demonstration of its confidence in Fosun Pharma’s intrinsic value.
The announcement comes as Fosun Pharma reported continued improvement in earnings quality during the first half of 2026, supported by increasing contributions from innovative medicines and international markets.
For H1 2026, the company reported revenue of RMB 20.44 billion, up 4.75% year-on-year.
Profit attributable to shareholders of the listed company, excluding non-recurring gains and losses, rose 19.09% to RMB 1.14 billion, while net cash generated from operating activities increased 13.59% to RMB 2.42 billion.
The buyback will be primarily funded through proceeds from Fosun Pharma’s disposal of approximately 6% of its equity stake in Gland Pharma, for total consideration of around US$294 million.
Following completion of the transaction, Fosun Pharma will retain an approximately 45.76% stake in Gland Pharma and continue to consolidate the Indian pharmaceutical company in its financial statements.
According to Fosun Pharma, net proceeds from the Gland Pharma transaction will be directed primarily towards R&D investment, share repurchases and repayment of interest-bearing debt.
The company said it remains confident in Gland Pharma’s long-term development and its role as a key contributor to Fosun Pharma’s international growth.